General Information							
Name of the Company*	Samrat Pharmachem Limited						
NSE Symbol*	NOTLISTED						
BSE Scrip Code*	530125						
MSEI Symbol*	NOTLISTED						
ISIN*	INE103E01016						
Type of Announcement*	New						
Type of Event*	Issue of duplicate share certificates/Letter of Confirmation						
Details of other event							
Date of original announcement							
Remarks (website dissemination)							
Remarks for Exchange (not for Website Dissemination)							
Date of Report	03-07-2025						

		Issue o	f Duplica	ite Sha	ire Cer	tificates	Letter of	Confirm	ation						
Number of shareholders to whom duplicate share certificate/Letter of Confirmation has been issued*								1							
Details of Shareholders to	o whom duplicat	e share cer	tificate/Lett	er of Co	nfirmatic	on has bee	n issued		***************************************	***************************************					
Date of receipt of information for issue of duplicate share certificate/Letter of Confirmation*	Name*	Folio Number	Number of Shares	Old Certificate Number		New Certificate/Letter of Confirmation Number		Distinctive Number		Reason for issue of duplicate share certificate/Letter of	Non- Compliance trigger				
				From	То	From	То	From	То	Confirmation	1950				
03-07-2025	RAVINDRA KUMAR	13959	1500	21799	21813	31002	31002	2179801	2181300	ORIGINAL LOST					
Name of Registrar and Transfer Agent (RTA) of the Company*								Others							
Name of other RTA								MUFG Intime India Private Limited							
Whether the Company has complied with Regulation 39 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*								Yes							
If No, specify the reason					***************************************	***************************************			***************************************						
Any other disclosure w.r.t	compliance of	any SEBI	Act, Regula	tion, Cir	cular or p	provision	ĺ	****************	***************************************						
Any other information					***************			***************************************							
Remarks (website dissem	ination)									***************************************	***************************************				
Remarks for Exchange (n	ot for Website d	isseminatio	n)						***************************************	***************************************					

Samrat Pharmachem Limited

From:

Alex Kundukulangara <alex.kundukulangara@in.mpms.mufg.com>

Sent:

03 July 2025 11:09

To:

Samrat Pharmachem Limited

Cc:

'Aqueel Mulla'

Subject:

RE: Approval date duplicate-Samrat Pharmachem Limited

Attachments:

0013959 challan.pdf; TN52 DUPLICATE REGISTER.pdf

Dear Ma'am,

Please find attached duplicate register for your record purposes.

Request you to kindly scan and share signed copy of the register before dispatching the same.

Thanks and Regards

Alex Kundukulangara Associate – Client Relations



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services (Formerly Link Intime India Private Limited)

C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083. www.in.mpms.mufg.com | Follow us: LinkedIn

T: +91 22 4918 6000 M: +91 9619790927 (Ext: 2329)

alex.kundukulangara@in.mpms.mufg.com



Do you really need to print this email?

From: Samrat Pharmachem Limited <contact@samratpharmachem.in>

Sent: 02 July 2025 16:06

To: Alex Kundukulangara <alex.kundukulangara@in.mpms.mufg.com>

Cc: 'Aqueel Mulla' <aqueelmulla@gmail.com>; 'Samrat Pharmachem Limited' <contact@samratpharmachem.in>

Subject: RE: Approval date duplicate-Samrat Pharmachem Limited

CAUTION: This email is received from an external domain. Open the hyperlink(s) & attachment(s) with caution.

Approval Date: 03-07-2025

Best Regards.

Sheetal

Samrat Pharmachem Limited

From: Alex Kundukulangara <a lex.kundukulangara@in.mpms.mufg.com>

Sent: 02 July 2025 03:41 PM

To: Samrat Pharmachem Limited < contact@samratpharmachem.in>

Cc: 'Aqueel Mulla' <aqueelmulla@gmail.com>

Subject: RE: Approval date duplicate-Samrat Pharmachem Limited

Dear Sir/Ma'am,

Kindly update as per trail mail.

Thanks and Regards

Alex Kundukulangara Associate – Client Relations



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services (Formerly Link Intime India Private Limited)

C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083. www.in.mpms.mufg.com | Follow us: LinkedIn

T: +91 22 4918 6000 M: +91 9619790927 (Ext: 2329) alex.kundukulangara@in.mpms.mufg.com



Do you really need to print this email?

From: Alex Kundukulangara Sent: 28 June 2025 11:03

To: Samrat Pharmachem Limited < contact@samratpharmachem.in>

Cc: 'Aqueel Mulla' <aqueelmulla@gmail.com>

Subject: Approval date duplicate-Samrat Pharmachem Limited

Dear Sir/Ma'am.

We have received duplicate request(s) for 1 shareholder.

Inward Certificate No.	Inward Certificate Date	Seller Folio	Seller Name	Buyer Folio No Buyer
DU1319	12/06/2025	0013959	RAVINDRA KUMAR	0013959

Kindly provide approval date for our further course of action.

Thanks and Regards

Alex Kundukulangara Associate - Client Relations



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services (Formerly Link Intime India Private Limited)

C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400 083. www.in.mpms.mufg.com | Follow us: <u>LinkedIn</u>

T: +91 22 4918 6000 M: +91 9619790927 (Ext: 2329) alex.kundukulangara@in.mpms.mufg.com



Do you really need to print this email?

DISCLAIMER: This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.

DISCLAIMER: This email (which includes any attachments or links to other websites) is intended solely for the named addressee. It is confidential and may contain legally privileged information. Delivery to any person other than the named addressee does not waive privilege or confidentiality. If you have received this email in error, let us know by reply email, delete it from your system and destroy any copies. This email is also subject to copyright. You must not reproduce or distribute it without our consent. We believe that information contained in this email is correct but we give no warranty as to its accuracy or completeness. It is provided as general information only and does not take into account your particular circumstances. It does not purport to be investment advice and you must not act in reliance on it. To the extent permitted by law, we disclaim all liability (including liability for negligence) for direct or indirect loss or damage suffered by

any recipient acting in reliance on this email. This email may contain information or links to websites prepared by people who are not our employees or representatives. Such information will be identified as the product of an independent third party. It is provided for your interest and convenience only. We have not independently verified (and to the extent permitted by law disclaim all liability for) its accuracy or completeness and it does not constitute our recommendation or opinion. Emails may be interfered with, may contain computer viruses or other defects and may not be successfully replicated on other systems. It is the responsibility of the recipient to verify the integrity and authenticity of this email and to ensure that any attachments are scanned for viruses.

FORWARDING NOTE CUM CHALLAN Challan No 03.07.2025 Date Name & Address of the Company: Samrat Pharmachem Limited 701 702 Business Square MA Road Andheri West Mumbai - 400058 Mr. Rajesh Mehta Kind Attention We are sending herewith the following documents for your kind perusal and approval for the lodgments received at our end for the various types of transactions enumerated herein below: Last date of Name of MICR No No of Received Folio No Type of shareholder (From/To) shares Date dispatch Transaction statutorily 0013959 RAVINDRA 1500 12/06/2025 12/07/2025 Duplicate KUMAR (Register only)

The type of transaction can be Transfers, Transmission, Name Deletion, Consolidation of Shares, Split of Shares, Duplicate of shares, Remat, Transposition, IEPF Claim Form 5

Please note that we have attached our working papers/check list like Stop Transfer Removal Check List, High Value Enhanced Due Diligence Check List to the relevant documents for your kind perusal.

Your attention is also drawn to the last date of dispatch which has to be statutorily adhered to for the type of transaction, indicated in the relevant column, hence you are requested to return the documents duly signed and authenticated to ensure timely dispatch.

Please return a copy of this Forwarding Note duly signed after perusal of the documents and the relevant work sheets / check lists which are supporting documents of our checking and due diligence.

For MUFG Intime India Private Limited (formerly Link Intime India Private Limited)

Authorised Signatory

The undersigned have perused the documents along with the work papers and duly authorize the transaction and have signed the share certificates and are forwarding the documents back to Link Intime India Limited for dispatch to the shareholder

Date of Approval: Name & Designation: Signature with stamp:



SAMRAT PHARMACHEM LIMITED REGISTER OF NEW SHARE CERTIFICATES ISSUED ON DUPLICATION FROM: TNS2 TO:-TNS2

Tr.no /Appr.Dt F	FOLIO NO. SHAREHOLDER'S NAME	CERT.NO		DIST.NOS		OULL DED	PAID VALUE	STUS	Deno	Cert Type	MICR From	MICR To
		FROM	TO	FROM	TO	SHARES	PAID VALUE	5105	Deno	Cort Type	WHOICHTOIL	IIII OI (TO
TN52 03/07/2025	0013959 RAVINDRA KUMAR	21799 31002	21813	2179801 2179801	2181300 2181300	1500 OLD 1500 1500 NEW	10	DUP	1500			

PRINTED ON: 03/07/2025

Page On: 1



SAMRAT PHARMACHEM LIMITED

 TOTAL NO.OF REQUESTS
TOTAL NO.OF OLD CERTIFICATES
TOTAL NO.OF NEW CERTIFICATES : 15 4. TOTAL NO.OF PAGES : 2

 TOTAL NO.OF DUPLICATED CERTIFICATE
TOTAL NO.OF DUPLICATED SHARES : 1500 7. TOTAL NO.OF SUB DIVIDED CERTIFICATE : 0 8. TOTAL NO.OF SUB DIVIDED SHARES : 0 9. TOTAL NO.OF CONSOLIDATED CERTIFICATE 0 10. TOTAL NO.OF CONSOLIDATED SHARES

Page On: 2